SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.
“At Alumis, we are committed to advancing precision medicines that transform the lives of people with autoimmune diseases and one of the key components to achieving that goal is building an exceptional team around us in order to execute,” said Martin Babler, president and chief executive officer of Alumis. “As we continue to advance our company and pipeline, the expertise of Sara and John and their histories leading legal and financial functions, respectively, will be critical to our success as an organization. I am thrilled to welcome them to the Alumis team and look forward to partnering with them on the exciting road ahead as we work to bring important medicines to those who need them.”
Sara Klein previously served as head of legal at Principia Biopharma following the company’s acquisition by Sanofi, and as senior vice president, legal prior to the acquisition. In these roles, Ms. Klein led legal, intellectual property and compliance functions. Prior to joining Principia, Ms. Klein held roles in the private practice of law, representing life science and technology companies. She started her career at the law firm of Baker & McKenzie, followed by five years as an in-house lawyer at Genentech. Ms. Klein received a B.A. in political science and French from Middlebury College and her law degree from the University of California, Hastings College of the Law.
John R. Schroer joins Alumis from ArsenalBio where he served as chief financial officer. Prior to that role, Mr. Schroer served as chief financial officer and treasurer at Translate Bio. From January 2014 to April 2018, Mr. Schroer served as a director and sector head – healthcare at Allianz Global Investors, a global asset management company. From 2009 to December 2013, he served as president and chief investment officer at Schroer Capital, LP, a financial services company that he founded. Mr. Schroer received a B.S. in history and international relations and an MBA from the University of Wisconsin-Madison.
Alumis is a precision immunology company looking to eliminate the “all comer” approach that is seen with today’s treatments for people with autoimmune disease. Even with innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, development and immunology, in order to create medicines that change the lives of people with autoimmune disease. For more information, please visit alumis.com.